Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMOSTXF)

Drug Name
Rigosertib Drug Info
Synonyms
Rigosertib; 592542-59-1; UNII-67DOW7F9GL; 67DOW7F9GL; N-[2-Methoxy-5-({[(E)-2-(2,4,6-Trimethoxyphenyl)ethenyl]sulfonyl}methyl)phenyl]glycine; ON-01910.Na; Rigosertib [USAN:INN]; 6FS; Rigosertib (USAN); AC1OCFT5; SCHEMBL498624; Estybon (proposed trade name); SCHEMBL498623; GTPL7833; CHEMBL1241855; ON01910.Na; DTXSID30207984; CHEBI:124939; OWBFCJROIKNMGD-BQYQJAHWSA-N; 1910 Na; ZINC3942646; BCP08296; BDBM50060917; 4006AH; AKOS015966442; DB12146; SB16468; (E)-2-((2-methoxy-5-(((2,4,6-trimethoxystyryl)sulfonyl)methyl)phenyl)amino)acetic a
Cross-matching ID
PubChem CID
6918736
ChEBI ID
CHEMBL1241855
CAS Number
CAS 592542-59-1
TTD Drug ID
D0KF9Q

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Salmonella infection 2.21 0.00e+0 198/249 (79.52%) TUBB2A;PODXL;CXCL8;...
NF-kappa B signaling pathway 2.10 0.00e+0 90/104 (86.54%) CXCL8;CXCL3;CD14;...
Amoebiasis 2.09 0.00e+0 99/102 (97.06%) CXCL8;CXCL3;ACTN1;...
IL-17 signaling pathway 2.04 0.00e+0 84/94 (89.36%) CXCL8;CXCL3;FOSL1;...
Chagas disease 2.04 0.00e+0 93/102 (91.18%) CXCL8;JUN;IL1B;...
TNF signaling pathway 2.02 0.00e+0 103/112 (91.96%) CXCL3;JUN;IL1B;...
Focal adhesion 1.99 1.74e-3 180/201 (89.55%) CAV1;ACTN1;FLNA;...
Shigellosis 1.95 3.04e-3 180/246 (73.17%) CXCL8;ACTN1;ACTN4;...
Pathogenic Escherichia coli infection 1.91 8.11e-3 152/197 (77.16%) TUBB2A;CXCL8;JUN;...
Legionellosis 1.89 8.52e-3 51/57 (89.47%) CXCL8;CXCL3;CD14;...
ECM-receptor interaction 1.80 1.55e-2 80/88 (90.91%) THBS1;ITGA6;ITGB4;...
Epithelial cell signaling in Helicobacter pylori infect... 1.80 1.52e-2 62/70 (88.57%) CXCL8;CXCL3;JUN;...
NOD-like receptor signaling pathway 1.78 1.59e-2 145/181 (80.11%) CXCL8;CXCL3;JUN;...
Lipid and atherosclerosis 1.76 2.09e-2 190/215 (88.37%) CXCL8;CXCL3;JUN;...
Rheumatoid arthritis 1.76 2.03e-2 78/93 (83.87%) CXCL8;CXCL3;JUN;...
Mineral absorption 1.75 1.98e-2 48/60 (80%) MT1E;MT1H;MT1G;...
Hypertrophic cardiomyopathy 1.75 1.93e-2 81/90 (90%) TPM1;TPM4;ITGA6;...
VEGF signaling pathway 1.74 2.03e-2 50/59 (84.75%) PRKCA;HSPB1;SPHK1;...
Tight junction 1.74 1.92e-2 130/169 (76.92%) ACTN1;ACTN4;JUN;...
AGE-RAGE signaling pathway in diabetic complications 1.74 1.95e-2 97/100 (97%) CXCL8;F3;JUN;...
Pertussis 1.74 1.85e-2 64/76 (84.21%) CXCL8;JUN;CD14;...
Apoptosis 1.73 1.99e-2 126/168 (75%) BIRC5;JUN;CAPN2;...
Vasopressin-regulated water reabsorption 1.69 2.91e-2 40/44 (90.91%) ARHGDIA;ARHGDIB;DYNC1I2;...
Dopaminergic synapse 1.69 2.94e-2 115/132 (87.12%) KIF5B;PRKCA;PPP2CB;...
Progesterone-mediated oocyte maturation 1.68 3.11e-2 75/100 (75%) PLK1;AURKA;CCNB2;...
Tuberculosis 1.67 3.28e-2 159/180 (88.33%) CD14;IL1B;SPHK1;...
Neutrophil extracellular trap formation 1.67 3.24e-2 101/189 (53.44%) PRKCA;NFKB1;NCF2;...
Dilated cardiomyopathy 1.67 3.13e-2 86/96 (89.58%) TPM1;TPM4;ITGA6;...
MAPK signaling pathway 1.65 3.44e-2 272/294 (92.52%) FLNA;JUN;PRKCA;...
Renal cell carcinoma 1.65 3.49e-2 68/69 (98.55%) JUN;CDKN1A;PAK4;...
Taurine and hypotaurine metabolism -1.63 4.65e-2 8/11 (72.73%) CSAD;CDO1;GGT5;...
Arachidonic acid metabolism -1.63 4.71e-2 48/61 (78.69%) CYP4F2;CYP4F3;PLA2G6;...
Glycolysis / Gluconeogenesis -1.66 4.18e-2 56/67 (83.58%) TPI1;ALDH9A1;AKR1A1;...
Steroid hormone biosynthesis -1.66 4.04e-2 43/61 (70.49%) CYP7B1;AKR1C4;UGT2B15;...
Pentose phosphate pathway -1.70 2.75e-2 25/30 (83.33%) GPI;G6PD;RBKS;...
Sulfur metabolism -1.71 2.66e-2 9/10 (90%) SUOX;TST;SELENBP1
One carbon pool by folate -1.76 1.65e-2 15/20 (75%) FTCD;MTHFR;DHFR;...
Alanine, aspartate and glutamate metabolism -1.78 1.59e-2 27/37 (72.97%) GLUD2;ABAT;PPAT;...
Folate biosynthesis -1.82 5.63e-3 23/26 (88.46%) GPHN;ALPL;SPR;...
Glutathione metabolism -1.83 6.44e-3 43/57 (75.44%) GSS;GSTM1;GSTK1;...
Pentose and glucuronate interconversions -1.83 7.51e-3 17/34 (50%) AKR1A1;AKR1B1;UGP2;...
Glyoxylate and dicarboxylate metabolism -1.90 1.50e-3 23/30 (76.67%) MDH2;ACO1;MDH1;...
Tryptophan metabolism -1.91 1.88e-3 35/42 (83.33%) EHHADH;KYAT1;ALDH7A1;...
Glycosylphosphatidylinositol (GPI)-anchor biosynthesis -1.92 2.50e-3 20/26 (76.92%) PIGG;PIGN;PIGV;...
Glycine, serine and threonine metabolism -2.01 0.00e+0 31/40 (77.5%) CBS;GRHPR;AGXT;...
Metabolism of xenobiotics by cytochrome P450 -2.06 0.00e+0 49/77 (63.64%) GSTM1;ADH1C;ADH1B;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone marrow
Neuroblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
SH-SY5Y CVCL_0019 Homo sapiens 0.04uM - 10uM 24H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.04uM - 10uM 6H, 24H
MDA-MB-231 CVCL_0062 Homo sapiens 0.08uM - 10uM 6H, 24H
SK-BR-3 CVCL_0033 Homo sapiens 0.08uM - 10uM 6H, 24H
Breast carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BT-20 CVCL_0178 Homo sapiens 0.08uM - 10uM 6H, 24H
Hs 578T CVCL_0332 Homo sapiens 0.08uM - 10uM 6H, 24H
Fibrocystic breast disease
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A (Parent) CVCL_0598 Homo sapiens 1.11uM - 10uM 3H, 6H, 12H, 24H
Normal (Epithelial)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HME1 CVCL_2950 Homo sapiens 0.04uM - 10uM 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.04uM - 10uM 6H, 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.04uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.04uM - 10uM 24H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 0.04uM - 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.04uM - 10uM 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEK293 CVCL_0045 Homo sapiens 0.04uM - 10uM 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 0.04uM - 10uM 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.04uM - 10uM 24H
A549/Asc-1 CVCL_YA87 Homo sapiens 0.04uM - 10uM 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 0.04uM - 10uM 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.04uM - 10uM 24H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.04uM - 10uM 24H
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.04uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.04uM - 10uM 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.04uM - 10uM 24H
SK-L CVCL_1699 Homo sapiens 0.04uM - 10uM 24H
Umbilical vein
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HUVEC-C CVCL_2959 Homo sapiens 0.04uM - 10uM 24H